Article Text

PDF
Letters
European Medicines Agency withdrawal for sibutramine
  1. J Galhardo1,
  2. N Davis1,
  3. S Matthai2,
  4. J P Shield1
  1. 1Bristol Royal Hospital for Children, Bristol, UK
  2. 2Department of Paediatrics, Gloucestershire Royal Infirmary, Gloucester, UK
  1. Correspondence to Julian P Shield, Bristol Royal Hospital for Children, Upper Maudlin Street, Bristol BS2 8AE, UK; j.p.h.shield{at}bristol.ac.uk

Statistics from Altmetric.com

In January 2010, the European Medicines Agency withdrew its approval for sibutramine and the Food and Drug Administration has restricted its license based on concerns about a raised cardiovascular risk found in the Sibutramine Cardiovascular Outcome Trial (SCOUT) preliminary report.1 2 Despite being contraindicated in poorly controlled hypertension and cardiovascular disease, SCOUT only recruited patients ≥55 years old with known cardiovascular disease or type 2 diabetes plus ≥1 additional risk factor for cardiac disease. Moreover, patients were treated for 5 years, when the recommended period for clinical practice is 12 months. Given the premorbid characteristics of the SCOUT cohort, we …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.